The Biomarkers Consortium Launches I-SPY 2 Breast Cancer Clinical Trial | Business Wire

Links shared publicly online about this topic.

1,308
total visits

The Biomarkers Consortium Launches I-SPY 2 Breast Cancer Clinical Trial | Business Wire

BETHESDA, Md.--(BUSINESS WIRE)--The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an im

View full resource at businesswire.com

Tags: Cancer, Breast Cancer, Drug, Pharma, Clinical Trial, Women's Health, FDA, National Institutes of Health